Mereo BioPharma (MREO)

• Market cap: $54.4M
• 1 day: -5.18%
• 5 days: -11.63%
• 1 month: -19.32%
• 3 months: -85.07%
• 6 months: -81.51%
• Year to date: -32.99%
• 1 year: -86.64%
• 5 years: -91.74%
• 10 years: -94.74%
• Sector: Healthcare
• Industry: Biotechnology

About: Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Employees: 36